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cardio-metabolic risk: is there is a place for
obstructive sleep apnea?
Aibek E MirrakhimovAbstract
Background: Obstructive sleep apnea is a common disorder acting as a risk factor for the development and
progression of cardiometabolic derangements including non-alcoholic fatty liver disease. Recent research data suggest
that non-alcoholic fatty pancreatic disease may be a more sensitive marker than non-alcoholic fatty liver disease for early
subclinical metabolic risk and may contribute to the progression of subclinical disease to overt type 2 diabetes mellitus.
Presentation of the hypothesis: We postulate that obstructive sleep apnea may be a risk factor for non-alcoholic fatty
pancreatic disease. It is well known that intermittent hypoxia related to obstructive sleep apnea leads to hormonal
derangements. Excessive lipolysis, enhanced lipid synthesis and systemic and local inflammation may favor ectopic fat
deposition similarly to non-alcoholic fatty liver disease. Furthermore, it is possible that obstructive sleep apnea can lead
to pancreatic beta cell damage via intermittent hypoxia.
Testing of the hypothesis: Future research should focus on the following: first, whether non-alcoholic fatty pancreatic
disease is an independent risk factor for the development of metabolic disease including diabetes mellitus or is a simple
consequence of obesity; second, the prevalence of non-alcoholic fatty pancreatic disease among people with obstructive
sleep apnea and vice versa, which should be compared to the prevalence of these diseases in general population; third,
whether coexistence of these conditions is related to greater cardiometabolic risk than either disease alone; and fourth,
whether the treatment of obstructive sleep apnea will translate into the resolution of non-alcoholic fatty pancreatic disease.
Implications of the hypothesis: If proven, this hypothesis will provide new knowledge on the complex interplay
between various metabolic insults. Second, screening for NAFPD may identify individuals at risk for developing type 2
diabetes mellitus for targeted prevention. Third, screening for the presence of non-alcoholic fatty pancreatic disease in
patients with obstructive sleep apnea may help to decrease the incidence of diabetes mellitus through a targeted
prevention.
Keywords: Obstructive sleep apnea, Non-alcoholic fatty liver disease, Non-alcoholic fatty pancreatic disease,
Cardiometabolic risk, Pancreatitis, Pancreatic cancerIntroduction
Obstructive sleep apnea (OSA) is a disorder that is char-
acterized by complete or partial breathing disturbances
during sleep with a minimum prerequisite frequency of
five events per hour, each of which should last for at
least 10 seconds [1]. These events occur as a result of
anatomical and/or physiological features of the upper
airways and their neural control or due to craniofacialCorrespondence: amirrakhimov1@gmail.com
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unless otherwise stated.parameters [2]. Its prevalence varies in epidemiological
surveys, which can be attributed to the different popula-
tions being studied, as well as to whether or not daytime
sleepiness is considered an inclusion criterion for OSA
diagnosis [3]; therefore, the percentage of the affected
population may be much larger than reported.
Recent data suggests that OSA is strongly associated
with cardiovascular, metabolic and even malignant disease
and may be an independent risk factor for their occur-
rence [4-11]. Nonalcoholic fatty liver disease (NAFLD) is
considered to be a manifestation of metabolic syndromeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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well as renal disease [12-14]. On the other hand, NAFLD
may independently contribute to insulin resistance [15]
and vascular stiffness [16]. Furthermore, NAFLD is con-
sidered to be among the leading causes of liver cirrhosis
and hepatocellular carcinoma [17]. Robust scientific data
indicates that OSA is strongly related to NAFLD inde-
pendently from traditional risk factors [5,18-20].
More recently, however, the fatty infiltration of pan-
creas or nonalcoholic fatty pancreatic disease (NAFPD)
was shown to correlate with metabolic risk [21]. In-
deed, NAFPD was shown to precede the development
of NAFLD, and, thus, may serve as a metabolic risk
marker [22].
From a theoretical standpoint, the presence of NAFPD
may explain why obese patients have worse outcomes
than their lean counterparts in acute pancreatitis [23]. It
is possible that NAFPD may follow the route of NAFLD
in terms of association with the development of organ-
specific cancer. However, a single-center study per-
formed by Sipe et al. did not find an association between
NAFPD and pancreatic cancer [24]. At the same time,
obesity and a fat-rich diet were shown to be strongly re-
lated to an increased risk of pancreatic cancer [25-27].
Indeed the above interrelationship between an unhealthy
metabolic profile and lifestyle may be mediated via
NAFPD. Whether, on a biological level NAFPD behavior
vary from simple steatosis to a more aggressive steato-
pancreatitis similarly to NAFLD spectrum is a matter for
future research. If so, steatopancreatitis may increase the
risk of pancreatic cancer and explain the association be-
tween obesity and pancreatic cancer [25-27].
We hypothesize that OSA is an extra hit for the devel-
opment of NAFPD and subsequent metabolic risk. It is
interesting to note that OSA may mediate hypoxic dam-
age to pancreatic beta-cells and, thus, lead to type 2 DM
[28]. Below we will formulate our hypothesis. Second,
we will review our current understanding of how OSA
leads to ectopic fat deposition, which is mainly based on
our understanding of NAFLD. Third, the potential meta-
bolic implications of NAFPD will be discussed. Finally,
we will discuss what steps need to be taken by the
research community to investigate whether OSA is a
mediator of cardiovascular and metabolic risk via its re-
lationship with NAFPD.
Hypothesis
We hypothesize that OSA may mediate its detrimental
cardiovascular and metabolic effects through the devel-
opment of ectopic fat deposition in pancreatic tissue.
OSA and ectopic fat deposition: a model of NAFLD
Recent data strongly suggest that OSA is an important
contributing factor for the occurrence of dyslipidemia[29,30]. The pathogenesis of the above association is me-
diated by at least three major processes such as enhanced
lipolysis in adipose tissue, decreased lipid clearance and
upregulated lipid synthesis in the liver. A review of
the literature on NAFLD and OSA by Mirrakhimov and
Polotsky noted factors that play key pathobiological roles
in the pathogenesis of NAFLD in the setting of OSA [5].
Intermittent hypoxia (IH) is a key mediator of OSA and
leads to various alterations in biological homeostasis [31].
First of all, it activates the sympathetic nervous system via
the carotid body chemoreceptors, which in turn leads to
fat degradation (lipolysis) from adipose tissue. Free fatty
acids (FFA) compose the triglycerides (a major form of fat
storage in the body; another major constituent of triglyc-
erides is glycerol), which are transported to different or-
gans to serve as fuel. However, FFA can lead to steatosis
and organ inflammation, such as in the setting of NAFLD.
At the same time, IH activates hypoxia inducible factors 1
and 2 (HIF-1 and HIF-2 respectively), which lead to de-
creased lipid metabolism in the liver, increased hepatic fat
synthesis, upregulated liver inflammation and fibrosis. The
HIF family is thought to play a major role both in physio-
logic adaptation as well as in the pathophysiology of dis-
ease states [32]. Indeed, the activation of HIF seems to
play a key role in the development and pathogenesis of
cancer [32-35]. Therefore, the previously described rela-
tionship between OSA and cancer [8-11] may be mediated
via the HIF pathway.
More recently a study by Minville et al. showed that
OSA and more specifically, nocturnal hypoxia was
demonstrated to be independently associated with liver
steatosis in obese individiuals further supporting the
independent interrelationship between OSA and meta-
bolic diseases [19]. Furthermore, a recent meta-analysis
by Sookoian and Pirola showed that patients with OSA
have greater transaminase values, higher prevalence of
NAFLD and liver fibrosis compared to individuals without
OSA [20].
An important question is whether OSA is independ-
ently (adjusted for confounders such as body mass index
(BMI), smoking, age, gender, alcohol intake, family his-
tory etc.) associated with organ-specific cancers [11]. Of
particular importance is to study whether OSA is linked
to hepatocellular carcinoma via its association with the
occurrence of NAFLD.
We hypothesize that OSA may contribute to the oc-
currence of NAFPD in a similar fashion as it does to
NAFLD. Future studies should assess whether OSA is a
true independent risk factor for the occurrence of
NAFPD, given that NAFPD may precede NAFLD [20]
and thus, may be an early marker of excess in cardiac
and metabolic risk. Therefore, identifying patients with
NAFPD and OSA even without clinically overt metabolic
disease such as metabolic syndrome or type 2 DM would
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the future development of type 2 diabetes mellitus, which
is a major contributor to excessive morbidity and mortal-
ity worldwide.
NAFPD and metabolic risk
The relationship between metabolic health and fatty in-
filtration of the pancreas is a well-known phenomenon,
which was first described in 1926 by Schaefer, who
showed a correlation between the weight of the human
body and that of the pancreas [36]. In 1933 Ogilvie dem-
onstrated that obese cadavers had heavier pancreatic
glands than non-obese cadavers [37]. Both of these pion-
eer studies suggested that pancreatic weight goes in par-
allel with body weight. It seems that this association may
now be explained by ectopic fat deposition in pancreatic
tissue.
Several animal studies have investigated the effects of fat
deposition in pancreas. Shimabukuro et al. demonstrated
that FFA induced apoptosis of pancreatic beta- cells
(endocrine cells producing insulin) in Zucker diabetic fatty
rats [38]. Mathur et al. showed that obese mice had heav-
ier pancreata with excessive fat infiltration and enhanced
production of pro inflammatory cytokines [39]. Lee et al.
demonstrated fat accumulation in both the exocrine and
endocrine pancreas in a rat model [40]. These researchers
speculated that fatty infiltration of the endocrine pancreas
may impair insulin secretion and thus lead to type 2 DM.
Tushuizen et al. studied 12 males with type 2 DM and
24 age- and BMI-matched non-diabetic men [41]. These
researchers demonstrated that pancreatic fat was inde-
pendently (adjusted for BMI, fasting plasma glucose and
triglycerides) associated with worse pancreatic beta cell
function. Lee et al. showed that NAFPD was associated
with higher levels of insulin resistance, visceral adiposity,
triglycerides and alanine aminotransferase compared to
normal pancreata [22].
Subsequently, scientific studies showed that increased
age, obesity, visceral steatosis, hypertension and type 2
DM were associated with the presence of NAFPD [42-45].
Nevertheless, it is essential to admit that NAFPD is under-
studied entitiy and not much is known about the natural
course of NAFPD. Available evidence suggests that men
have a higher prevalence of NAFPD compared to women
with the same BMI, insulin resistance and fat intake
[46,47]. Certain groups may also have a greater prevalence
of NAFPD. For example it was shown that Hispanics had
greater pancreatic fat content than African-Americans
[48]. These observations may explain why men and cer-
tain ethnic groups have increased metabolic risk profiles.
Most studies to date have investigated patients at risk
for type 2 DM and, thus, the prevalence may be overesti-
mated. Several imaging modalities can be of use in quan-
tifying pancreatic fat such as trans abdominal and transesophageal ultrasound, computed tomography and mag-
netic resonance tomography [44-46,49-51]. However,
NAFPD is currently the focus of research rather than
the clinical community given scarce data on natural his-
tory and information on whether screening for NAFPD
will translate into decreased morbidity and mortality.
In a pig model Hanukkainen et al. demonstrated
that pancreatic fat is associated with insulin resistance
and liver fat content [52]. However, van Geenen et al.
showed that the association between pancreatic fat and
liver fat is mediated via central obesity [53]. Heni et al.
demonstrated that pancreatic fat was negatively associated
with insulin secretion in patients with pre-diabetes [54].
These researchers suggested that this effect may contrib-
ute to the progression of pre-diabetes to overt type 2 DM.
van der Zijl et al. also demonstrated that patients with
pre-diabetes had greater pancreatic fat content [55]. How-
ever, this group was unable to demonstrate a relationship
between pancreatic fat and insulin secretion. On the other
hand, insulin resistance was found to be strongly associ-
ated to the presence of pancreatic fat [56]. Sepe et al.
found a close interrelationship between NAFPD and me-
tabolic syndrome [24]. However, no correlation was found
between NAFPD and pancreatitis, pancreatic cancer and
DM.
More recently two studies from Taiwan were published
on the association between NAFPD and metabolic risk. In
a first study, Wu and Wang confirmed an intricate associ-
ation between NAFPD and metabolic risk factors [21].
They retrospectively studied 557 subjects without known
hypertension and DM for the prevalence of NAFPD.
12.9 % of subjects were found to have NAFPD via transab-
dominal ultrasonography. Older age, greater BMI, abdom-
inal waste circumference and metabolic variables such as
glycated hemoglobin, lipid parameters and systolic blood
pressure were associated with the presence of NAFPD. In
a second study, Ou et al. enrolled 7,464 individuals to
assess prevalence of NAFLD and NAFPD [57]. These re-
searchers found that NAFPD was associated with pre-
diabetes and DM after adjustment for cardiometabolic
variables. It is interesting to note that NAFPD was only
found to be associated with the presence of pre-diabetes
and DM in male subjects, but not in females. The lack of
association between female gender, NAFPD and metabolic
risk may be explained by the study methodology, lower
prevalence of NAFPD compared to NAFLD and possible
gender specific patterns of ectopic fat deposition. A sum-
mary of key clinical studies investigating fatty pancreas is
presented in Table 1.
Future research is needed to clarify whether NAFPD is
a simple consequence of obesity or indeed, an independ-
ent player in the development of metabolic complica-
tions such as type 2 DM. It will also be interesting to
investigate whether the presence of NAFPD is related to
Table 1 Summary of human studies investigating pancreatic fat deposition
First author and year Country Study design Population studied Findings
Al-Haddad et al. 2009 [44]. USA Case control study using
endoscopic ultrasound.
120 subjects (60 females). 60 subjects were found to have
evidence of fatty pancreas.
Patients with fatty pancreas had greater BMI (mean BMI
31.7 kg/m2 vs. BMI 25.4 of people without fatty pancreas),
higher prevalence of fatty liver (57% vs 5%) and excessive
alcohol use.




293 subjects from obesity clinic (166 females). Patients
with diabetes mellitus, thyroid disease, liver disease,
pancreatic disease, renal disease and individuals with
excessive alcohol use were excluded from the study.
180 subjects were found to have NAFPD. Male gender, greater
BMI, waist circumference, visceral fat, alanine aminotransferase
levels, triglyceride levels, fasting insulin levels and insulin
resistance were strongly associated with NAFPD.
Choi et al. 2010 [45]. South Korea Case control study using
endoscopic ultrasound.
284 individuals (182 females). Subjects with history of
pancreatic disease, hepatobiliary disease or gastrointestinal
malignancy were excluded. 110 patients were found to
have evidence of fatty pancreas.
Presence of fatty liver, visceral fat, hypertension, male gender
and older age were associated with ultrasonographic
evidence of fatty pancreas.





51 individuals (26 females) at risk for type 2 DM. 23 patients
(14 females) were found to have pre-diabetes.
Greater BMI, waist circumference and visceral adipose tissue
were associated with higher pancreatic fat content.
Pancreatic fat was negatively associated with decreased
insulin secretion in patients with pre-diabetes.
Sepe et al. 2011 [24]. USA Prospective case control
study using endoscopic
ultrasound.
230 subjects (114 females) underwent endoscopic ultrasound.
64 individuals were found to have fatty pancreast (37 females).
Increased BMI and fatty liver were strongly associated with
ultrasonographic evidence of fatty pancreas. No association
was found between pancreatitis, pancreatic cancer and
fatty pancreas.
Rossi et al. 2011 [47]. Italy Cross sectional study
using magnetic resonance
imaging.
41 individuals (21 females). Subjects with fasting plasma
glucose ≥7.0 mmol/l (≥126 mg/dl) and drinking >30 g/day
for men and >20 g/day for women were excluded.
38 subjects were found to be obese (20 females).
Obese individuals had greater pancreatic fat content as well
as other metabolic derangements such as visceral adiposity
and fatty liver. Obese women had statistically lower amount
of pancreatic and liver fat, visceral adiposity despite similar
BMI. Visceral adipose tissue was found to be the strongest
predictor for pancreatic and liver fat deposition.
Wu and Wang 2013 [21]. Taiwan Cross-sectional study
using trans abdominal
ultrasound.
557 individuals (342 females) without history of hypertension
and DM. 72 subjects (42 females) were found to have fatty
pancreatic disease.
Older age, higher BMI and waist circumference, glycemic
control, lipid parameters and systolic blood pressure were
associated with the presence of fatty pancreas.
Ou et al. 2013 [57]. Taiwan Cross-sectional study
using trans abdominal
ultrasonography.
7,464 subjects (2871 females). 483 patients were found to
have DM (155 females). 18.1% of men and 14.2% of
women were found to have fatty pancreas.
Fatty pancreas was found to be independently associated
with pre-diabetes and DM in males.
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ance is whether NAFPD represents a risk factor for the
occurrence of exocrine pancreatic cancer.
Implication of the hypothesis
We postulate that NAFPD is an early marker of in-
creased cardiac and metabolic risk. NAFPD may precede
clinically overt metabolic disease (such as NAFLD, meta-
bolic syndrome and type 2 DM) and, thus, would be a
useful marker of cardiometabolic risk in any individual.
Therefore, identifying such individuals is of paramount
importance since early intervention may reduce the bur-
den of type 2 DM and cardiovascular disease. On the
other hand, OSA was shown to be a risk factor for a
myriad of cardiac and metabolic complications such as
cardiovascular disease, hyperlipidemia, type 2 DM and
NAFLD. Of particular note, NAFLD is a spectrum of
metabolic syndrome and is related to a greater risk of
vascular disorders. It was reported that OSA is a con-
tributing factor for the development of NAFLD, and
through this mechanism may lead to a greater risk of
type 2 DM. Furthermore, OSA may exert hypoxic dam-
age to pancreatic β-cells and lead to the occurrence of
type 2 DM in susceptible individuals.
Further studies are needed to clarify whether OSA is
related to NAFPD. Studies assessing the prevalence of
NAFPD in patients with OSA (and vice versa) may be
needed initially. The results of such studies should be
adjusted for common confounders such as age, gender,
BMI and obesity, metabolic syndrome, type 2 DM,
hyperlipidemia and alcohol intake. Subsequently, longi-
tudinal studies of OSA patients will be needed to assess
the impact of OSA on pancreatic fatty infiltration and
the natural history of NAFPD. Studying the natural his-
tory of NAFPD (with and without concomitant OSA) is
of paramount importance and such research should give
answers to the following question: is NAFPD truly a be-
nign disease or is it associated with subclinical pancreatic
inflammation and a resultant increase in the severity of
clinical cases of acute pancreatitis, pancreatic insufficiency
(both exocrine and endocrine) and pancreatic cancer. In
turn, it should be determined whether OSA is a key player
in the development of the above complications.
These research questions somewhat parallel those
which have been asked about NAFLD, a sister disorder
of NAFPD. NAFLD was found to be a non-benign dis-
ease, with some patients progressing to liver cirrhosis
and hepatocellular cancer. Whether the same is true for
NAFPD is a matter for future research.
Conclusion
OSA is a common disorder acting as a risk factor for the
development and progression of various cardiometabolic
derangements. Of note, OSA seems to be an independentrisk factor for the development of NAFLD. Recent re-
search data suggest that NAFPD may be a more sensitive
marker for early subclinical metabolic risk than NAFLD
and may contribute to the progression of subclinical dis-
ease to overt type 2 DM. We postulate that OSA may be a
risk factor for NAFPD as well. OSA may mediate NAFPD
via tissue hypoxia, lipolysis and fat deposition in pancre-
atic tissue with resultant derangements in pancreatic func-
tion. Future studies should investigate the association
between OSA and NAFPD as well as give us prospective
data on the natural history of NAFPD.
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